title: Patient reported health outcomes and non-adherence in psoriasis patients receiving adalimumab or ustekinumab for moderate to severe plaque psoriasis.
abstract: OBJECTIVE
  The objective of this study is to compare health outcomes of patients using biologic therapies ustekinumab (UST) or adalimumab (ADA) for moderate-to-severe plaque psoriasis (PsO) and assess biologics non-adherence.
  
  
  METHODS
  Two phases of web-based survey data were collected, assessing adult patients with PsO from a Diplomat® Specialty Pharmacy US claims database (Diplomat Specialty Pharmacy; Flint, MI). Measures included demographics, treatment and health characteristics/behaviors, treatment satisfaction, health-related quality of life (HRQoL), and productivity. Pooled and stratified (by biologics experience) bivariate and multivariable analyses were conducted.
  
  
  RESULTS
  UST (n = 262) versus ADA (n = 83) users more frequently had psoriasis cleared (40.5% versus 15.4%, respectively, with no visible signs), better HRQoL as per Dermatology Life Quality Index (DLQI) score = 0 (45.2% versus 19.2%), and higher current effectiveness satisfaction, all p < 0.05. Adjusting for covariates, UST versus ADA bio-naïve patients (n = 68) had better (53.4% lower) DLQI scores, lower percent body surface affected (%BSA; 0.85 versus 1.43), more %BSA improvement (-1.60 versus -1.03), and lower activity impairment (90.4% lower), all p < 0.05. Non-adherence to UST (11.8%) versus ADA (32.5%) was lower, p < 0.05, and more access versus forgetfulness-related. However, no significant differences emerged on outcomes between overall or bio-experienced UST and ADA users.
  
  
  CONCLUSIONS
  UST versus ADA PsO bio-naïve patients reported higher clearing rates, better DLQI, and lower activity impairment.
authors.affiliation: a Kantar Health , New York , NY , USA and.
authors.forename: Amir
authors.initials: A
authors.lastname: Goren
authors.affiliation: b Janssen Scientific Affairs , LLC, Horsham , PA , USA.
authors.forename: Chureen
authors.initials: C
authors.lastname: Carter
authors.affiliation: b Janssen Scientific Affairs , LLC, Horsham , PA , USA.
authors.forename: Seina
authors.initials: S
authors.lastname: Lee
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D000069549:Ustekinumab / Q000008:administration & dosage / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000069549:Ustekinumab; D000068879:Adalimumab
keywords: Activity impairment; health-related quality of life; non-adherence; treatment satisfaction; work productivity